Organon & Co. OGN
13.91 USD -0.01 (-0.07%)
Regular-session close
13.91 0.00 0.00%
After hours · Nov 19, 4:07 PM ET
13.90 Day range 13.94
5.69 52-week range 13.94
- YTD
- +94.00%
- 1 year
- +86.71%
News
businesswire.com Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI JERSEY CITY, N.J.--(BUSINESS WIRE)--ACAAI- new pooled post-hoc analysis of VTAMA (tapinarof) cream, 1% demonstrates consistent response for atopic dermatitis disease severity and itch.
zacks.com Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.benzinga.com Reported Saturday, Organon Presents Real-World Data At ACR Showing 1.3% Switchback Rate After Over 16,000 US Veterans Switched From HUMIRA To HADLIMA Analysis of over 16,000 patients switched to HADLIMA® from HUMIRA® (adalimumab) showed a 1.3% switchback rate over a 12-month follow-up period1Data demonstrated the switching cohort had an average…
benzinga.com Organon To Present New Analysis Of Phase 3 Data Evaluating VTAMA Cream In Patients With Atopic Dermatitis, At 2026 ACAAI Annual Scientific Meeting New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroupsOrganon (NYSE:OGN), a global healthcare company with a…
defenseworld.net Contrasting CASI Pharmaceuticals (NASDAQ:CASI) and Organon & Co. (NYSE:OGN) Organon and Co. (NYSE: OGN - Get Free Report) and CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies…
zacks.com Organon (OGN) Q3 Earnings and Revenues Top Estimates Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.
businesswire.com Organon Announces Quarterly Dividend JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces Quarterly Dividend.
zacks.com Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
businesswire.com Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third…
defenseworld.net Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses…
businesswire.com Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
zacks.com Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
accessnewswire.com Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold VANCOUVER, BC / ACCESS Newswire / October 13, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement…
accessnewswire.com Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British Columbia VANCOUVER, BC / ACCESS Newswire / October 8, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement…
zacks.com Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
businesswire.com Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.
zacks.com Is Trending Stock Organon & Co. (OGN) a Buy Now? Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
defenseworld.net VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $770,000 Investment in Organon & Co. $OGN VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Organon and Co. (NYSE: OGN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 56,850…
businesswire.com Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
accessnewswire.com Orogen Royalties Acquires the Serpent Gold Project in Nevada VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in…
zacks.com Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
accessnewswire.com Orogen Royalties Acquires Two Gold Projects in Southwest Utah VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El…
